Balancing Benefits and Risks: Patients’ Experiences With Newer Therapies and Side Effects in Late-Line RRMM

Panelists discuss how physician-patient conversations about newer multiple myeloma therapies have evolved to include detailed discussions of potential benefits (higher response rates, novel mechanisms of action) alongside unique toxicity profiles (cytokine release syndrome with immunotherapies, neurotoxicity with CAR-T, skin/nail issues with GPRC5D-targeted agents), with patients sharing diverse experiences ranging from minimal side effects to significant complications that required hospitalization, emphasizing the importance of thorough preparation, proactive management strategies and realistic expectations when embarking on these innovative but potent treatment approaches.